Switching from Mounjaro to Wegovy: the questions forum threads can't fully answer

What forums get right, and where they run out of road

If you search for experiences of switching from Mounjaro to Wegovy, you'll find no shortage of people sharing their stories. Some switched because of side effects; some because of supply issues; some because their circumstances changed. Those accounts are genuine and worth reading. The problem is that forum posts almost always describe a single person's body, dose, starting weight and medical context, none of which is yours.

What forums rarely cover: the pharmacological difference that matters for a switch decision, whether tolerance built up on one drug carries over to the other, how the licensed eligibility criteria compare, or what clinical red flags might make a switch inadvisable. These aren't gaps people are hiding; they're things that require a prescriber to assess.

There's also a safety angle that's easy to miss in a thread. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines under UK law. A switch isn't a consumer decision; it's a clinical one. Any forum advice suggesting otherwise (however well-meaning) is working beyond its competence. Our page on switching from Mounjaro to Wegovy covers the practical process in full.

How the two medicines compare on mechanism and trial evidence

Mounjaro is a dual GIP and GLP-1 receptor agonist, it activates two gut-hormone pathways involved in appetite regulation and blood-sugar control. Wegovy acts on only the GLP-1 pathway. If you want a fuller breakdown of how these two medicines sit apart from each other, our page covering the difference between Wegovy and Mounjaro sets out what that distinction means in practice.

On average weight loss, the trial data favours Mounjaro at its higher doses. In the SURMOUNT-1 trial (involving 2,539 adults with obesity), tirzepatide produced around 20–21% average body-weight reduction at 15mg over 72 weeks, as published in the New England Journal of Medicine. Wegovy at 2.4mg produced around 15% in the STEP 1 trial over 68 weeks. In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide again produced greater average weight reduction than semaglutide 2.4mg. NICE's appraisal of tirzepatide (TA1026) notes that indirect comparisons favour tirzepatide on this measure.

That said, the gap narrows with Wegovy's newer 7.2mg dose, approved by the MHRA in January 2026, which reported around 20.7% average weight loss over 72 weeks. Some people also respond better to one mechanism than the other, trial averages don't predict individual outcomes.

Source: NICE TA1026 (tirzepatide); NICE TA875 (semaglutide); NEJM trial publications.

The specific things a switch decision turns on

Someone considering moving from Mounjaro to Wegovy (or thinking about the reverse) is usually asking one of a few underlying questions: has the weight loss stalled at my current dose? Am I struggling with side effects that might be mechanism-specific? Has something in my medical history changed? Could cost or supply availability be driving this?

Each of those has a different clinical answer. A plateau on Mounjaro at a mid-range dose is handled differently from a plateau at 15mg. Side effects that are GI-driven are common to both medicines and may not improve on a switch; side effects tied to the GIP pathway would be a different conversation. Our prescribers look at the full picture (current dose, weight trajectory, comorbidities, any concurrent medicines) before recommending anything.

The oral contraceptive interaction is one forum threads rarely flag clearly: if you're on Mounjaro and using the pill, NHS guidance advises adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because absorption may be reduced. Wegovy does not carry the same specific advisory. That's a clinical detail that belongs in a prescriber conversation, not a forum comment. Our overview of how a switch works clinically goes into more of these specifics.

If you've previously switched in the other direction, the considerations shift again, there's a separate set of questions that arise when moving back to Mounjaro from Wegovy, which our prescribers handle as a fresh clinical review.

How a prescriber-led review resolves what forums leave open

This is probably the thing people sitting in forum threads feel most acutely: you can read fifty posts and still not know what applies to you. That's not a failure of research, it's the nature of prescription medicine. The answer to whether switching is right for you genuinely requires someone to look at your case.

At nume, that means a free consultation reviewed by a real prescriber (not a scoring algorithm) on the same day. If you're transferring from an existing treatment, you'll be asked for evidence of your current dose and recent weight. A switch, if clinically appropriate, is handled as a new clinical assessment: your prescriber considers whether the change makes sense, what starting dose is right, and whether anything in your history or current medicines needs accounting for.

You can explore the full range of options on the weight-loss treatments page, or read a direct comparison of Wegovy versus Mounjaro if you want more on the evidence side before you consult. The cost picture between the two is covered on the Wegovy vs Mounjaro cost page. Which medicine suits you is a clinical decision, one our prescribers make with you, not for you.